M. R. Rinder, R. E. Richard and H. M. Rinder, “Acquired von Willebrand Disease: A Concise Review,” American Journal of Hematology, Vol. 54, No. 2, 1997, pp. 139-145.
http://dx.doi.org/10.1002/(SICI)1096-8652(199702)54:2<139::AID-AJH7>3.0.CO;2-Y

has been cited by the following article:

• TITLE: Acquired von Willebrand Syndrome in a Male with Systemic Lupus Erythematosus Presented with Mucocutaneous Bleeding and Treated with rFVIIa

  AUTHORS: Maryam Hami, Hassan Ahmadnia, Zahra Rezaieyazdi, Hassan Mansouritorghabeh

  KEYWORDS: Acquired von Willebrand Disease; Lupus Erythematosus Systemic; rFVIIa; Bleeding

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.1, January 8, 2014

  ABSTRACT: Background: Systemic lupus erythematosis (SLE) is a disorder with multiple organ involvement. Haematological abnormalities have been addressed in it, but acquired von Willebrand syndrome is a rarer phenomenon in current disease. The Case: We report acquired von Willebrand syndrome and SLE in a man with brown rash on face, gingival bleeding, easy bruising and epistaxis and laboratory finding of decreased complement, high level of anti-nuclear antibody and anti-DNA. These findings confirmed the diagnosis of SLE. He underwent kidney biopsy and experienced severe pain at the site of biopsy, but the ultra-sonography evaluation showed small sub capsular haematoma at the site of biopsy. During the next 48 hours, gradually APTT prolongation was continued and haematocrit dropped. In spite of FFP infusion and taking tranexamic acid every eight hours, there wasn’t any improvement in haemostatic condition. He received Methylprednisolone and Cyclophosphamid pulses. The patient underwent surgery to roll out vascular complication, but there wasn’t any vascular problem. On the third day, recombinant activated factor VII was infused every two hours until oozing was stopped.